Sangamo Therapeutics Stock Forecast, Price & News

-0.22 (-2.17 %)
(As of 07/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume18,502 shs
Average Volume1.25 million shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sangamo Therapeutics logo

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.35 out of 5 stars

Medical Sector

840th out of 2,214 stocks

Biological Products, Except Diagnostic Industry

122nd out of 211 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

Is Sangamo Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sangamo Therapeutics stock.
View analyst ratings for Sangamo Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sangamo Therapeutics?

Wall Street analysts have given Sangamo Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sangamo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Sangamo Therapeutics

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.03. The biopharmaceutical company earned $26.30 million during the quarter, compared to analysts' expectations of $24.20 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 24.82% and a negative net margin of 94.38%. The firm's quarterly revenue was up 100.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.37) EPS.
View Sangamo Therapeutics' earnings history

How has Sangamo Therapeutics' stock price been impacted by Coronavirus?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGMO stock has increased by 41.6% and is now trading at $9.94.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SGMO?

5 equities research analysts have issued twelve-month price objectives for Sangamo Therapeutics' shares. Their forecasts range from $16.00 to $29.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $22.40 in the next year. This suggests a possible upside of 125.4% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 58, Pay $1.2M)
  • Mr. Gary H. Loeb, Exec. VP, Gen. Counsel, Chief Compliance Office & Sec. (Age 51, Pay $612.2k)
  • Dr. R. Andrew Ramelmeier Ph.D., Exec. VP of Technical Operations (Age 59, Pay $675.48k)
  • Mr. D. Mark McClung, Exec. VP & Chief Bus. Officer (Age 58, Pay $568k)
  • Ms. Prathyusha Duraibabu CPA, M.B.A., Sr. VP & CFO (Age 42)
  • Dr. Jason D. Fontenot Ph.D., Sr. VP & Chief Scientific Officer (Age 51)
  • Ms. Aron Feingold, Head of Corp. Communications & Investor Relations Officer
  • Ms. Whitney Jones, Sr. VP & Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow, Sr. VP of Product Devel. & Management
  • Ms. Heather Erickson, Chief of Staff

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among Sangamo Therapeutics' employees.

Who are some of Sangamo Therapeutics' key competitors?

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Compagnie Lombard Odier SCmA (0.01%). Company insiders that own Sangamo Therapeutics stock include Gary Loeb, H Stewart Parker, Joseph S Zakrzewski, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends for Sangamo Therapeutics

Which institutional investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Gary Loeb, Rolf Andrew Ramelmeier, and Saira Ramasastry.
View insider buying and selling activity for Sangamo Therapeutics
or view top insider-selling stocks.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $9.94.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics has a market capitalization of $1.43 billion and generates $118.19 million in revenue each year. The biopharmaceutical company earns $-121,000,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics employs 413 workers across the globe.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is

Where are Sangamo Therapeutics' headquarters?

Sangamo Therapeutics is headquartered at 7000 MARINA BLVD, BRISBANE CA, 94005.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]

This page was last updated on 7/26/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.